Avanos Medical, INC. (AVNS) — SEC Filings

Q: What are the key financial highlights for Avanos Medical, INC.?

Key financial highlights for Avanos Medical, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Avanos Medical, INC.?

Key executives at Avanos Medical, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Avanos Medical, INC. stock?

Risk factors for Avanos Medical, INC. (AVNS) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Avanos Medical, INC.?

Forward-looking statements and predictions from Avanos Medical, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Avanos Medical, INC.. Recent DEFA14A filing on Apr 14, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Avanos Medical, INC. on SEC EDGAR

Overview

Avanos Medical, INC. (AVNS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 14, 2026: On April 13, 2026, Avanos Medical, Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as the 8-K document itself, an exhibit 2.1, and exhibit 99.1, along with graphical elements and XBRL data. The company's mailing and business address is 5405 Windw

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 3 bearish, 31 neutral. The dominant filing sentiment for Avanos Medical, INC. is neutral.

Filing Type Overview

Avanos Medical, INC. (AVNS) has filed 1 DEFA14A, 14 8-K, 3 8-K/A, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 5 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (34)

DEFA14A Filing — DEFA14A · Apr 14, 2026
Avanos Medical Files 8-K: Material Agreement Details — 8-K · Apr 14, 2026 Risk: medium
On April 13, 2026, Avanos Medical, Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as the 8-K document its
8-K/A Filing — 8-K/A · Dec 5, 2025
AVANOS Swings to $71.6M Loss on Goodwill Impairment — 10-Q · Nov 5, 2025 Risk: high
AVANOS MEDICAL, INC. reported a net loss of $1.4 million for the three months ended September 30, 2025, a significant decline from a net income of $4.3 million
Avanos Medical CFO Departs; New Directors Appointed — 8-K · Oct 23, 2025 Risk: medium
On October 21, 2025, Avanos Medical, Inc. announced the departure of its Chief Financial Officer, Robert J. Blount, effective October 25, 2025. The company also
Avanos Medical Files 8-K — 8-K · Sep 15, 2025 Risk: low
Avanos Medical, Inc. filed an 8-K on September 15, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Halyard
Avanos Medical Swings to Q2 Loss Amid Revenue Dip — 10-Q · Aug 5, 2025 Risk: high
AVANOS MEDICAL, INC. reported a net loss of $10.0 million for the three months ended June 30, 2025, a significant decline from a net income of $5.0 million in t
Avanos Medical Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: low
Avanos Medical, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Halyard Health, Inc., is based in Alpharett
Avanos Medical Announces Director Changes and CEO Compensation — 8-K · Apr 30, 2025 Risk: medium
On April 28, 2025, Avanos Medical, Inc. filed an 8-K report detailing the departure of Director Dr. Steven R. Smith and the appointment of Dr. Brian L. King as
Avanos Medical Files 8-K/A Amendment — 8-K/A · Apr 28, 2025 Risk: low
Avanos Medical, Inc. filed an 8-K/A on April 28, 2025, to amend a previous filing. The amendment pertains to the departure of a director, the election of a new
Avanos Medical Files 8-K on Shareholder Votes and Financials — 8-K · Apr 25, 2025 Risk: low
On April 24, 2025, Avanos Medical, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements and exhib
Avanos Medical Files 8-K/A Amendment — 8-K/A · Apr 18, 2025 Risk: low
Avanos Medical, Inc. filed an 8-K/A on April 18, 2025, to amend a previous filing. The amendment pertains to the departure of a director, election of a new dire
Avanos Medical Announces Board Changes and Compensation Updates — 8-K · Mar 17, 2025 Risk: low
On March 14, 2025, Avanos Medical, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the elec
Avanos Medical Files Proxy Statement for 2025 Annual Meeting — DEF 14A · Mar 14, 2025 Risk: low
Avanos Medical, Inc. filed its definitive proxy statement on March 14, 2025, for its annual meeting on April 24, 2025. The filing details executive compensation
Avanos Medical Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
Avanos Medical, Inc. filed its 2024 10-K on February 26, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, fo
AVANOS MEDICAL, INC. Files 8-K Report — 8-K · Jan 13, 2025 Risk: low
On January 13, 2025, AVANOS MEDICAL, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
Avanos Medical Files 8-K on Officer Departures & Director Elections — 8-K · Dec 3, 2024 Risk: medium
On December 2, 2024, Avanos Medical, Inc. filed an 8-K report detailing the departure of certain officers and the election of new directors. The filing also inc
SC 13G Filing — SC 13G · Nov 14, 2024
Avanos Medical Files 8-K with Financials — 8-K · Nov 4, 2024 Risk: low
Avanos Medical, Inc. filed an 8-K report on November 4, 2024, detailing events that occurred on November 1, 2024. The filing primarily concerns financial statem
Avanos Medical Files Q3 2024 10-Q — 10-Q · Oct 30, 2024 Risk: low
Avanos Medical, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position during the thi
Avanos Medical Files 10-Q for Q2 2024 — 10-Q · Jul 31, 2024 Risk: medium
Avanos Medical, Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter and the first half of the fiscal year. Key financi
Avanos Medical Appoints New CFO, Steven Ramey — 8-K · Jul 1, 2024 Risk: medium
On June 28, 2024, Avanos Medical, Inc. announced the appointment of Steven L. Ramey as its new Chief Financial Officer, effective July 1, 2024. Ramey will recei
Avanos Medical Files 8-K: Regulation FD & Exhibits — 8-K · May 13, 2024 Risk: low
On May 13, 2024, Avanos Medical, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No spec
Avanos Medical, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
AVANOS MEDICAL, INC. (AVNS) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Avanos Medical, Inc. filed a 10-Q report for the period ending March 31
Avanos Medical Files 8-K on Shareholder Votes and Financials — 8-K · Apr 29, 2024 Risk: low
On April 25, 2024, Avanos Medical, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The fili
Avanos Medical, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Mar 15, 2024 Risk:
AVANOS MEDICAL, INC. (AVNS) filed a Proxy Statement (DEF 14A) with the SEC on March 15, 2024. Avanos Medical, Inc. filed a Definitive Proxy Statement (DEF 14A)
Avanos Medical, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 21, 2024 Risk: low
AVANOS MEDICAL, INC. (AVNS) filed a Annual Report (10-K) with the SEC on February 21, 2024. Avanos Medical, Inc. filed its annual report for the fiscal year end
AVANOS MEDICAL Files 8-K on Financial Condition — 8-K · Feb 20, 2024 Risk: low
AVANOS MEDICAL, INC. filed an 8-K on February 20, 2024, to report on its results of operations and financial condition. The filing, under SEC file number 001-36
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Dimensional Fund Advisors Amends Avanos Medical Stake — SC 13G/A · Feb 9, 2024 Risk: low
Dimensional Fund Advisors LP, a major investment firm, filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of Avanos Medical I
Paradice Investment Management Cuts Avanos Medical Stake to 6.1% — SC 13G/A · Feb 7, 2024
Paradice Investment Management LLC, an investment firm, filed an amended Schedule 13G/A on February 7, 2024, disclosing its ownership in Avanos Medical, Inc. As
BlackRock Amends AVNS Stake, Maintains Passive Position — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 22, 2024, indicating its ownership of AVANOS MEDICAL, INC. common stock as of December 31, 2023. This
AVANOS MEDICAL Files 8-K on Operations & Financial Condition — 8-K · Jan 4, 2024
AVANOS MEDICAL, INC. filed an 8-K on January 4, 2024, to report on its Results of Operations and Financial Condition, along with Financial Statements and Exhibi

Risk Profile

Risk Assessment: Of AVNS's 25 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Avanos Medical, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $520.3M
Net Income: ($71.6M)
EPS: ($1.55)
Cash Position: $70.5M
Total Assets: $1,067.7M

Key Executives

Alpharetta, Georgia
Chief Operating Decision Maker
Robert J. Blount
Todd W. Miller
David L. Johnson
Michael J. Prevoznik
Dr. Steven R. Smith
Dr. Brian L. King
Lourdes R. Reyes
Steven L. Ramey

Industry Context

Avanos Medical operates in the medical device industry, a sector characterized by innovation, regulatory scrutiny, and consolidation. The company focuses on areas like advanced wound care and digestive health. Key trends include the shift towards value-based care, increasing demand for minimally invasive solutions, and the impact of global supply chain dynamics on manufacturing and distribution.

Top Tags

financials (6) · 10-Q (5) · corporate-governance (5) · amendment (4) · regulatory-filing (3) · SEC Filing (3) · board-of-directors (3) · sec-filing (3) · Avanos Medical (3) · institutional-ownership (3)

Key Numbers

CIK Number: 0001606498 — Identifies Avanos Medical, Inc. in SEC filings.
File Number: 001-36440 — SEC file number for Avanos Medical, Inc.
Net Loss: $71.6M — for the nine months ended September 30, 2025, compared to $5.2M net income in 2024
Goodwill Impairment: $77.0M — charge for the nine months ended September 30, 2025
Net Sales: $177.8M — for the three months ended September 30, 2025, up 4.3% from $170.4M in 2024
Gross Profit: $86.0M — for the three months ended September 30, 2025, down from $92.9M in 2024
Cash and Cash Equivalents: $70.5M — as of September 30, 2025, down from $107.7M at December 31, 2024
Capital Expenditures: $24.7M — for the nine months ended September 30, 2025, up from $13.0M in 2024
Acquisition of assets and investments in businesses: $28.3M — for the nine months ended September 30, 2025
Basic Loss Per Share: $1.55 — from continuing operations for the nine months ended September 30, 2025
Common Stock Outstanding: 46,418,907 — as of October 29, 2025
Net Loss (Q2 2025): $10.0M — Significant swing from $5.0M net income in Q2 2024
Revenue (Q2 2025): $150.0M — 3.2% decrease from $155.0M in Q2 2024
Net Loss (YTD June 2025): $18.0M — Reversal from $8.0M net income YTD June 2024
Revenue (YTD June 2025): $300.0M — 2.5% decrease from $307.7M YTD June 2024

Forward-Looking Statements

{"claim":"Dimensional Fund Advisors will continue to be a significant institutional holder of Avanos Medical stock.","entity":"Dimensional Fund Advisors LP","targetDate":"Next 12 months","confidence":"high"}

Frequently Asked Questions

What are the latest SEC filings for Avanos Medical, INC. (AVNS)?

Avanos Medical, INC. has 34 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AVNS filings?

Across 34 filings, the sentiment breakdown is: 3 bearish, 31 neutral. The dominant sentiment is neutral.

Where can I find Avanos Medical, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Avanos Medical, INC. (AVNS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Avanos Medical, INC.?

Key financial highlights from Avanos Medical, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AVNS?

The investment thesis for AVNS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Avanos Medical, INC.?

Key executives identified across Avanos Medical, INC.'s filings include Alpharetta, Georgia, Chief Operating Decision Maker, Robert J. Blount, Todd W. Miller, David L. Johnson and 5 others.

What are the main risk factors for Avanos Medical, INC. stock?

Of AVNS's 25 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Avanos Medical, INC.?

Recent forward-looking statements from Avanos Medical, INC. include guidance on {"claim":"Dimensional Fund Advisors will continue to be a significant institutional holder of Avanos Medical stock.","en.